

### Shakir Mahmood Alwan

Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Bab Al-Moadham, P. O. Box 14026, Iraq

Abstract: An approach of using molinspiration calculations and molecular docking on PBPs (penicillin-binding proteins) and certain  $\beta$ -lactamases is employed to predict the molecular properties, bioactivity and resistance of newer and reference cephalosporins. The previously synthesized cephalosporins 1-8 and reference cephalosporins were subjected to extensive evaluations by calculating the molecular properties, drug-likeness scores on the bases of Lipinski's rule and bioactivity prediction using the method of molinspiration web-based software. The TPSA (topological polar surface area), OH-NH interactions, n-violation and the molinspiration Log partition coefficient (miLogP) values were also calculated. The investigated cephalosporins were subjected to molecular docking study on PBPs (1pyy) and on  $\beta$ -lactamases produced by S. aureus, K. pneumonia, E. coli and P. auroginosa using 1-click-docking website. Molecular properties of 1-8 recorded higher TPSA than cephalexin and were lower than the reference cephalosporins and do not fulfill the requirements for Lipinski's rule. Bioactivities of 1-8 were predicted to be less and their docking scores on PBPs were comparable to those of the reference cephalosporins, particularly ceftobiprole. The references recorded various docking scores on the above  $\beta$ -lactamases. Molecular docking studies on PBPs and  $\beta$ -lactamases are considered as very useful, reliable and practical approach for predicting the bioactivity scores and to afford some information about the stability and selectivity of the newly proposed cephalosporins against  $\beta$ -lactamases of certain pathogenic microbes, such as P. auroginosa and MRSA, by recording the relative docking scores in comparison with those of reference cephalosporins.

Key words: Cephalosporins, Molinspiration, Molecular docking, β-lactamases, Lipinski's rule.

## 1. Introduction

Drug resistance is a serious situation that limits the treatment choices of infections caused by MRSA (methicillin-resistant *Staphylococcus aureus*). MRSA strains have spread worldwide and are considered as the most dangerous threat to humans [1-4] and the outbreaks of MRSA in the community have increased alarmingly. The widespread resistance of MRSA to  $\beta$ -lactam antibiotics has made treatment of infections by these antibiotics extremely difficult [5]. Besides,

*strains of S. aureus* have also become resistant to so-called "drugs of last choice" including vancomycin, linezolid and daptomycin [6-8]. The development of potent new drugs is one of the most difficult and complicated processes in pharmaceutical industry.

Cephalosporins are the most widely used  $\beta$ -lactam antibiotics for treatment of bacterial infections and perform their action through covalent binding with PBPs, thus inhibiting the final step in cell wall biosynthesis. The development of bacterial resistance is a major concern that encourages the development of new resistant antibiotics towards bacterial  $\beta$ -lactamases. Cephalosporins have different

**Corresponding author:** Shakir Mahmood Alwan, Ph.D. medicinal chemistry, assistant professor, chemical synthesis of new antimicrobial agents and prodrugs.

antibacterial spectra,  $\beta$ -lactamase sensitivity/ resistance and pharmacokinetic properties [9]. The fifth generation cephalosporins, ceftobiprole [10] and ceftaroline [11] are characterized by having unique spectrum on G (-) bacteria (powerful anti-Pseudomonal activity) and an expanded spectrum against G (+) bacteria include MRSA. Their activities are beyond all other cephalosporins and appear to be less susceptible to develop resistance. Ceftobiprole exhibits a high level of affinity for PBPs of MRSA [12].


CADD (computer-aided drug design) approach aims to shorten the time and tedious procedures and provide better efficiency in the processes of drug discovery. This approach provides more details and aid to coordinate the information to make the drug design more rational [13-15]. Rational drug design helps to facilitate and fasten the procedures of drug designing process, which includes various methods to identify and select the novel potent compounds. Molecular docking of a drug molecule with a certain receptor is one of these approaches [16].Docking is the binding or interaction of a ligand with targeted receptor in the 3-D (three dimensional structure) spaces in order to study the molecular properties and degree of binding that reflect its bioactivity [17-19]. There is an increasing interest and potential application of this approach in the field of drug design and discovery. The antibacterial activity of novel a-amino acid functionalized fluoroquinolones is validated by molecular docking studies and is in good correlation with the experimental results [20]. Docking study of polycyclic quinolone-based molecules revealed that these compounds recorded weak cytotoxic effects and poor binding affinity to human topoisomerase [21]. Results of docking paclitaxel and its analogues on target proteins tubulin B-1 chain and B-c1-2 showed various docking scores and predicted only two analogues as more suitable than paclitaxel [22]. Molecular docking studies of cyclic octapeptide (D-proline-incorporated wainunuamide) revealed more potent affinity for HPV18-2IOI (HeLa cancer cell lines) and exhibited better antitumor activity [23].


In view of the cumulative information, it was considered that CADD may be useful to design new cephalosporins of great potential and have better activities and properties, particularly β-lactamase resistant and antipseudomonal activity. Molecular docking as one of the CADD strategies was used for providing extensive molecular modeling calculations, bioactivity prediction and docking scores of cephalosporins to PBPs and *β*-lactamases from different sources. This approach may aid in the discovery of novel potent cephalosporins that are resistant to  $\beta$ -lactamases. Based on the author's knowledge, no docking study arising from the use of cephalosporins on  $\beta$ -lactamases have been reported, so far. Application of this approach was attempted on the previously synthesized cephalosporins [24], and selected reference cephalosporins representing the five generations that are susceptible or resistant to β-lactamases to confirm its validity.

## 2. Experimental

## 2.1 The Investigated Cephalosporins

Cephalosporins 1-8 were previously synthesized, characterized and identified and evaluated for their antimicrobial activities [24]. The chemical structures of 1-8 are given as supplementary information on Fig. 1. Reference cephalosporins selected from the five generations, that are of various degree of stability against  $\beta$ -lactamases were used, such as, cephalexin and cefuroxime (susceptible to hydrolysis by  $\beta$ -lactamases) and ceftazidime, ceftriaxone, cefozopran, and ceftobiprole (resistant to  $\beta$ -lactamases). Using one of the chemoffice softwares (ChemDraw Ultra 10.0 program), the chemical structures of all the investigated cephalosporins and their SMILES notation were obtained. Their chemical structures are illustrated on Fig. 1 and chemical nomenclature are as compounds 1-4 follows; [Substituted-3-(acetoxymethyl)-7-(2-(5-benzylidenea






mino)-1,3,4-thiadiazol-2-yl-thio)-acetamido)-8-oxo-5thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid] and compounds 5-8 [Substituted-3-(acetoxymethyl)-7-(2-((5-benzylidenea mino)-1,3,4-thiadiazol-2-yl)-disulfanyl)acetamido)-8oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid].

# 2.2 Calculation of Molecular Properties and Bioactivity Scores

Lipinski's rule of five [25, 26] was used to evaluate the drug-likeness and calculate the molecular properties that are essential factors for a drug (absorption, pharmacokinetics, including ADME distribution, metabolism excretion). and Molinspiration website-based software (www.molinspiration.com) was employed to obtain certain molecular parameters. The values of miLogP, as (octanol/water partition coefficient) and TPSA of the investigated cephalosporins were determined using the method developed by molinspiration [27]. Drug-likeness scores were calculated to represent the amount of fragments based on contributions and correction factors [28]. The prediction of bioactivity scores of these cephalosporins were calculated by recording the activity scores of GPCR (G-protein coupled receptors ligand), KI (kinase inhibitor), PI (protease inhibitor), EI (enzyme inhibitor), ICM (ion channel modulator) and NRL (nuclear receptor ligand).

# 2.3 Docking Study on PBPs (Penicillin Binding Proteins)

The docking study of the investigated cephalosporins on  $PBP_2$  (1pyy) was conducted to



confirm and support the antimicrobial activities of cephalosporins 1-8 [24] and to be compared with reference cephalosporins of various activities to validate this approach. This study was conducted using 1-click-docking software (mcule.com) and the chemical structures of PBPs were retrieved from the protein data bank (PDB, www.rcsb.org (DOI:10.2210/pdb3b60/pdb).

## 2.4 Docking Study on Certain $\beta$ -Lactamases

The structures of the bacterial  $\beta$ -lactamases were retrieved from PDB. Different  $\beta$ -lactamases of various bacteria were used for docking study of these cephalosporins to calculate the docking scores of the binding energies and consequently, investigate the possibility of resistance toward the above types of  $\beta$ -lactamases. These types of  $\beta$ -lactamases are; PDB (ID: 1xgj) of *E. coli*, PDB (ID: 3q6x) of *K. Pneumonia*, PDB (ID: 10me) of *S. aureus* and PDB (ID: 2wzz) of *P. auroginosa* 

### 3. Results and Discussion

## 3.1 Molinspiration Calculations

Molecular properties were calculated on the bases of Lipinski's rule and its components. The cephalosporins 1-8 have higher TPSA than cephalexin, particularly, 4 and 8 (196.98), which do not comply with Lipinski's rule (Table 1). Furthermore, TPSA values of the reference cephalosporins are higher (except for cephalexin) and increasing with advancing in generations, particularly, ceftriaxone (221.61) and ceftobiprole (203.18) and these do not comply with Lipinski's rule (Table 1). These cephalosporins largely differ in their ADME properties. The values of OH-NH polar fragments representing the proton donors and proton acceptors of 1-8 and the reference cephalosporins were 2 and 3 to 6 respectively (Table 1). The OH-NH values centered polar fragments should be <5 and  $\leq 10$  respectively, based on Lipinski's rule. Accordingly, cephalosporins 1-8 do not fulfill the requirements for Lipinski's rule. TPSA is a very useful descriptor used to characterize drug absorption and bioavailability, permeability through Caco-2 cells and transport across blood brain barriers [25, 26]. The higher values of TPSA and OH-NH interactions indicate that these compounds may have smooth and efficient binding to receptor, as compared with the reference cephalosporins (Table 1). However, drug molecules with TPSA values of 140 Å or higher are expected to have very low absorption [26]. Lipophilicity (miLogP) and TPSA values are essential factors for the prediction of oral bioavailability of drugs [29]. Molinspiration cheminformatics are available from http://www.molinspiration.com. TPSA values are high for ceftazidime, ceftriaxone and ceftobiprole (Table 1), which do not comply with Lipinski's rule, and as expected, since all these are administered parenterally. The n-violation values of

1-8 were 2, which is comparable with the reference cephalosporins.

#### 3.2 Prediction of bioactivity scores

prediction of bioactivity The scores of cephalosporins 1-8 were recorded by calculating the activity scores of GPCR ligand, ICM, NRL, KI, PI and EI (Table 2). Their predicted drug likeness scores were much less than those of the reference cephalosporins (Table 2). Likewise, 1-8 have consistent negative values in all categories and numerical values for those of the reference cephalosporins. Accordingly, all the synthesized cephalosporins 1-8 are predicted to have less activity than the reference cephalosporins used based upon those categories and these results comply with the previously reported activity evaluation [24]. The n-violation of cephalosporins 1-8 was 2, as compared with cephalexin which has zero violation and complies with Lipinski's rule. Cephalexin has good bioactivity and excellent absorption. The other reference cephalosporins, which are only used parenterally, have n-violation of 1-3 (Table 1). Drug likeness scores predicted poor bioactivities for the cephalosporins 1-8 and the results showed various values and are summarized on Table 2.

| Compound     | Molinspiration Calculations |        |        |                   |             |        |  |
|--------------|-----------------------------|--------|--------|-------------------|-------------|--------|--|
|              | MW                          | miLogP | TPSA   | OH-NH Interaction | n Violation | Volume |  |
| 1            | 533.6                       | 1.458  | 151.16 | 2                 | 2           | 421.85 |  |
| 2            | 568.1                       | 2.136  | 151.16 | 2                 | 2           | 435.38 |  |
| 3            | 612.5                       | 2.213  | 151.16 | 2                 | 2           | 439.73 |  |
| 4            | 578.6                       | 1.417  | 196.98 | 2                 | 2           | 445.18 |  |
| 5            | 565.7                       | 1.958  | 151.20 | 2                 | 2           | 439.97 |  |
| 6            | 600.1                       | 2.636  | 151.16 | 2                 | 2           | 453.51 |  |
| 7            | 644.7                       | 2.767  | 151.16 | 2                 | 2           | 457.86 |  |
| 8            | 610.6                       | 1.917  | 196.98 | 2                 | 2           | 463.31 |  |
| Cephalexin   | 347.4                       | -1.486 | 112.73 | 4                 | 0           | 293.2  |  |
| Cefuroxime   | 424.39                      | -0.978 | 173.77 | 4                 | 1           | 334.95 |  |
| Ceftazidime  | 547.6                       | -0.630 | 189.45 | 5                 | 2           | 442.52 |  |
| Ceftriaxone  | 540.6                       | -2.110 | 221.61 | 5                 | 2           | 405.45 |  |
| Cefozopran   | 515.5                       | -5.51  | 184.87 | 3                 | 2           | 400.75 |  |
| Ceftobiprole | 534.58                      | -1.504 | 203.18 | 6                 | 3           | 424.33 |  |

 Table 1
 Molinspiration calculations of the synthesized and reference cephalosporins.

Key notes: MW= molecular weight, miLogP = molinspiration Log partition coefficient, TPSA = topological polar surface area.

|              |               | o ,    |       | 1 1   |       |       |  |
|--------------|---------------|--------|-------|-------|-------|-------|--|
| Commence     | Drug-Likeness |        |       |       |       |       |  |
| Compound     | GPCR          | ICM    | KI    | NRL   | PI    | EI    |  |
| 1            | -1.05         | -1.22  | -1.3  | -1.14 | -0.18 | -0.27 |  |
| 2            | -1.02         | -1.21  | -1.28 | -1.12 | -0.20 | -0.29 |  |
| 3            | -1.09         | -1.26  | -1.30 | -1.19 | -0.26 | -0.31 |  |
| 4            | -1.07         | -1.26  | -1.01 | -1.13 | -0.27 | -0.34 |  |
| 5            | -0.79         | -1.10  | -1.01 | -1.01 | -0.06 | -0.01 |  |
| 6            | -0.77         | -1.11  | -1.00 | -0.99 | -0.09 | -0.04 |  |
| 7            | -0.84         | -1.15  | -1.02 | -1.06 | -0.14 | -0.06 |  |
| 8            | -0.83         | -1.18  | -1.05 | -1.03 | -0.15 | -0.12 |  |
| Cephalexin   | -0.35         | -0.73  | -1.03 | -0.98 | 0.5   | 0.13  |  |
| Cefuroxime   | -0.28         | -0.83  | -0.91 | -0.57 | 0.43  | 0.15  |  |
| Ceftazidime  | -0.23         | -0.75  | -0.57 | -0.70 | 0.24  | 0.29  |  |
| Ceftriaxone  | -0.18         | -0.73  | -0.80 | -1.07 | 0.03  | 0.33  |  |
| Cefozopran   | 0.071         | -0.498 | -0.75 | -1.16 | 0.19  | 0.39  |  |
| Ceftobiprole | -0.21         | -0.499 | -0.62 | -1.02 | 0.294 | 0.412 |  |

Table 2 Molinspiration drug-likeness of the synthesized and reference cephalosporins.

Key notes: GPCR = G-protein coupled receptor, ICM = Ion channel modulator, KI =Kinase inhibitor, NRL= Nuclear receptor ligand, PI = Protease inhibitor, EI = Enzyme inhibitor.

#### 3.3 Docking Scores of Cephalosporins on PBP2

Docking of a compound on a macromolecule allows recording a database and predicting the strongest and more potent binding affinity to a certain binding site. The antibacterial activity of cephalosporins against certain pathogenic microbes depends on its degree of binding affinity to specific PBPs in that microbe. There are a number of PBPs in each microbe, represented as PBP 1-6 with additional subtypes. The high or potent affinity towards only one type of PBPs is enough to show antibacterial action. Docking of 1-8 on PBPs were conducted to confirm and support the evaluation of their antimicrobial activities mentioned earlier [24]. This docking approach was also employed for the reference cephalosporins of various activities for comparison and to establish a relationship or a correlation. It may be suitable for predicting activity and stability against β-lactamases and anti-pseudomonal activities of the newly proposed cephalosporins. The docking scores of cephalosporins 1-8 on PBPs were -6.90 to -7.37 (Table 3). Moreover, compounds 2, 3, 4, and 6 recorded the lowest docking scores of -7.125, -7.025, -7.37 and -7.075 respectively, which may indicate that these have higher activities than the others and comparable with the reference

cephalosporins, particularly, ceftobiprole (Table 3). The docking pose of 4 (-7.37) is shown on Fig. 2. Docking pose of cephalexin on PBP2 (1pyy) was recorded on Fig. 3 to show the position of its functional groups on the surface of PBP2 and for comparison with other cephalosporins.

The docking score of 4 is very close to those of ceftazidime, ceftriaxone and ceftobiprole, which may indicate that it has strong affinity binding to PBPs and hence is equally potent. Interestingly, and as expected the docking scores of the reference cephalosporins are decreasing to lower values (Table 3), when advancing in generations, indicating potent affinity binding and




Fig. 2 Docking pose of cephalosporin 4 on pbp2 (1pyy).




Fig. 3 Docking pose of cephalexin on pbp2 (1pyy).

more activities. Ceftobiprole recorded the lowest docking score of -7.47, while cephalexin has higher docking score of -5.75 and this obviously means that ceftobiprole has higher binding affinity towards PBPs and much better activity than cephalexin. The detailed results are given on Table 3. Various β-lactam antibiotics exhibited different binding affinities for the PBPs of E. coli K-12 [30]. The affinities of these compounds for PBPs revealed close agreement with their antibacterial activities. Previous report [31] indicated that there is no correlation between the minimum inhibitory concentrations (MICs) and the binding affinity of certain cephalosporins, such as cefozopran for PBPs 1, 2 or 6. The results suggested that cefozopran has good activity against E. faecalis TN2005 by binding to PBP 5, while, ceftazidime and cefmenoxime have no affinity for PBP 5. Furthermore, ampicillin, benzyl penicillin and imipenem recorded higher affinity for PBP 3-5 than cefozopran, while their experimental activities were lower than that of cefozopran [31]. Ceftobiprole and ceftriaxone have good affinity for the PBP 2 with distinguished antibacterial activities [32, 33]. However, it was reported that there is no direct relationship between the amounts of expressed PBP 2a in different strains of MRSA and the  $\beta$ -lactam MICs [34]. Moreover, it was shown that ceftobiprole exhibited potent binding to PBP2x of penicillin-resistant S. pneumoniae, PBP2a of MRSA and PBP3 and other essential PBPs of methicillin susceptible S. aureus, E. coli, and P. aeruginosa [35]. Ceftobiprole also bind effectively to PBP2 in the latter organisms, contributing to its antibacterial activity against G (-) and G (+) bacteria [31]. Ceftaroline exhibited potent binding to many PBPs in S. aureus (PBP 2a), responsible for methicillin resistance of MRSA and to PBPs in S. pneumonia, PBP 2b, PBP 2x and PBP 1a, which is an important factor in penicillin resistance [36]. Moreover, it was confirmed that the binding affinities of several β-lactams correlated well with their respective MICs for various strains of MRSA [29, 37, 38]. β-Lactam antibiotics, which are substrate analogues, covalently bind to PBPs and inactivate them at concentrations that are approximately equal to their MICs [31]. The PBPs (1a, 1b) and PBP2 (2a, 2b, 2x) of S. pneumonia have high affinity for most  $\beta$ -lactams [31]. Certain  $\beta$ -lactam antibiotics were subjected to affinity binding study and were found to have a close correlation between their MICs and the concentrations required to saturate 50% of PBP 2b [39, 40]. However, this correlation was not apparent when the bacteria were previously exposed to these antibiotics at their MICs. Accordingly and based on all these studies and observations, it is concluded that correlation between MICs and the binding affinity is not a decisive matter to predict the activity and could not be relied on to find a link between activity (MICs) and binding affinity to PBPs. It is worth suggesting that docking of cephalosporins on PBPs and measuring the docking scores may have an excellent direct correlation with the activity of these antibiotics, when compared with docking results of the known reference antibiotics.

# 3.4 Docking Scores of the Investigated Cephalosporins on $\beta$ -Lactamases

The docking results of cephalosporins 1-8 on various  $\beta$ -lactamases were compared with those of the reference cephalosporins (Table 3). These recorded low docking scores on  $\beta$ -lactamase of *E. coli* (-7.15 to -7.85), which were within the same range of the docking scores of the reference cephalosporins, except

for ceftriaxone (-8.47) and ceftobiprole (-8.65). However, cephalosporins 2 and 3 recorded the lowest scores of (-7.85 for both) and this result may suggest that their binding affinities are higher than cephalexin, cefuroxime or ceftazidime toward E. coli, and consequently, may be more resistant to this β-lactamase. Cephalosporins 1 and 4 have the lowest docking scores of -7.07 and -7.40 on  $\beta$ -lactamase of K. pneumonia, respectively, which may suggest that these two cephalosporins are more resistant than cephalexin, cefuroxime or ceftazidime (Table 3). Docking of 5 and 6 on β-lactamase of *P. auroginosa* recorded the lowest docking scores of -8.65 and -8.85, respectively, and these may be more resistant than cephalexin, cefuroxime, or ceftazidime (Table 3). Docking scores of 2, 6 and 7 on  $\beta$ -lactamase of S. aureus were the lowest (-7.07), as shown on Table 3, and these cephalosporins are presumed to be more stable than all reference cephalosporins, except ceftobiprole (-7.3). These cephalosporins are also assumed to have potent interaction on the binding sites and their 3-dimentional structure may have great effect on the stability towards β-lactamases. The presence of Schiff bases and sulfide or disulfide bonds on either side of the 1,3,4-thiadiazole ring in the acyl side chain may contribute to the functionality of the structures that provide strong interaction with the binding sites rather than the active sites.

In these docking studies the red net that appeared on the surface of the  $\beta$ -lactamases in the diagrams (Figs. 4-10) represent the polar sites of the enzyme that aid in binding and catalysis of substrates. The white net represents the non-polar sites that do not contribute to any catalysis. It is obvious that when the  $\beta$ -lactam ring is accommodated within the polar active site, means the enzyme is capable of hydrolyzing this antibiotic. The docking of various cephalosporins presented as their 3D structures on  $\beta$ -lactamases (Figs. 4-10) showed clearly the positioning of the  $\beta$ -lactam ring on the surface of the enzyme. The  $\beta$ -lactam ring of these cephalosporins was projected away from the polar active site, while the polar groupings on either side of the cephem nucleus of the molecule interacted with the polar binding sites, and provided some degree of stability against β-lactamases. Docking poses of compounds 2-4 and 6 on  $\beta$ -lactamases were taken for comparison (Figs. 4-7), since those showed low docking scores (Table 3).

| Compound         |                 | —<br>—PBPs           |                   |                       |        |
|------------------|-----------------|----------------------|-------------------|-----------------------|--------|
| compound         | E. coli<br>1xgj | K. Pneumonia<br>3q6x | S. aureus<br>1ome | P. auroginosa<br>2wzz | 1pyy   |
| 1                | -7.80           | -7.07                | -6.85             | -8.50                 | - 6.90 |
| 2                | -7.85           | -6.95                | -7.07             | -8.55                 | -7.12  |
| 3                | -7.85           | -5.80                | -6.95             | -8.52                 | -7.02  |
| 4                | -7.47           | -7.40                | -6.9              | -8.42                 | -7.37  |
| 5                | -7.77           | -6.42                | -6.7              | -8.65                 | -6.97  |
| 6                | -7.50           | -5.72                | -7.07             | -8.85                 | -7.07  |
| 7                | -7.15           | -5.70                | -7.07             | -7.85                 | -6.95  |
| 8                | -7.47           | -6.95                | -7.0              | -7.60                 | -6.85  |
| cephalexin       | -6.95           | -6.35                | -6.35             | -7.60                 | -5.75  |
| cefuroxime       | -7.33           | -6.02                | -6.17             | -8.02                 | -6.1   |
| ceftazidime      | -7.40           | -6.80                | -6.75             | -8.17                 | -7.37  |
| ceftriaxone      | -8.47           | -7.20                | -6.92             | -9.32                 | -7.27  |
| cefozopran       | -8.3            | -7.0                 | -6.2              | -9.0                  | -7.40  |
| $ceftobiprole^+$ | -8.65           | -7.90                | -7.3              | -9.40                 | -7.47  |

| Table 3 D | <b>Docking scores of t</b> | e synthesized and | l reference ce | phalosporins. |
|-----------|----------------------------|-------------------|----------------|---------------|
|-----------|----------------------------|-------------------|----------------|---------------|

\*More negative values indicate higher binding affinity. Four docking poses were taken for each compound on each enzyme and scores represent the average. + Two docking poses appeared on *P. auroginosa* and *K. pneumonia* and only one pose appeared on *E. coli* and *S. aureus*.




Fig. 4 The best docking pose of cephalosporin 3 on 1xgj.




Fig. 5 The best docking pose of cephalosporin 4 on 3q6x.




Fig. 6 The best docking pose of cephalosporin 2 on 1ome.

# 3.5 Docking Scores of the Reference Cephalosporins on $\beta$ -Lactamases

Cephalexin and cefuroxime recorded high docking scores on all types of  $\beta$ -lactamases (-6.35 to -6.95) and (-6.02 to -7.33) and this means that they needed high




Fig. 7 The best docking pose of cephalosporin 6 on 2wzz.

energy of binding. These two cephalosporins are susceptible to hydrolysis by all β-lactamases and recorded high docking scores (Table 3). The resistant cephalosporins (ceftazidime, ceftriaxone, cefozopran and ceftobiprole) recorded lower docking scores on all  $\beta$ -lactamases (Table 3) and ceftobiprole has always the lowest values (-7.3 to -9.4). Moreover, these cephalosporins recorded very low docking scores (-7.6 to -9.4) on P. auroginosa, which are supported by the known fact that these cephalosporins have antipseudomonal activities. However, the docking scores of the reference cephalosporins on  $\beta$ -lactamases of S. aureus, K. pneumonia and E. coli were -6.17 to -7.3, -6.02 to -7.9, and -6.95 to -8.65, respectively (Table 3). Ceftobiprole recorded the lowest docking scores on all types of  $\beta$ -lactamases (Table 3), and this is an expected result due to the fact that it is much more resistant. However, ceftriaxone showed comparable results to ceftobiprole with respect to E. coli, S. aureus and P. auroginosa (Table 3). These results indicated that the resistant cephalosporins have potent binding affinity to the binding sites of the  $\beta$ -lactamases but not on the active site of these enzymes. There is a clear evidence that docking of these resistant cephalosporins on  $\beta$ -lactamases showed that the  $\beta$ -lactam ring was projected away or flipped from the active site, and therefore is not hydrolyzed and consequently, showed greater stability against  $\beta$ -lactamases (Figs. 9 and 10). However, the  $\beta$ -lactam ring of cephalexin was

accommodated in a dense polar area, the red net (presumably the active site), which explains its susceptibility to hydrolysis by  $\beta$ -lactamases (Fig. 8). The docking scores on  $\beta$ -lactamases indicated that there is a direct relationship between the energy of the binding affinity, referring to the lowest docking scores and the stability. This means that these cephalosporins have more potent binding with much more stability, as shown for ceftobiprole (Table 3). The more convincing explanation for the strong binding of resistant cephalosporins with *β*-lactamases without suffering hydrolysis is that these cephalosporins interact with β-lactamases to form an acyl adduct or a complex. But once in this form, it is presumed that the polar substituents on either C7 side chain or C3 position force the electrophilic acyl group to rotate away or flipped and thus displayed from the site of hydrolysis by the active site of the enzyme. Furthermore, these polar substituents provide strong interaction to the binding sites (Figs. 9 and 10). An interesting finding was observed in the comparison of the structures of complexes of AmpC  $\beta$ -lactamase with ceftazidime and loracarbef (a substrate of  $\beta$ -lactamase), which illustrated that the structural conformation of ceftazidime in the active site differs from that of substrate [41]. This study suggested that ceftazidime inhibit the formation of the tetrahedral transition state, indicating that it is an inhibitor of AmpC  $\beta$ -lactamase, without suffering hydrolysis by this  $\beta$ -lactamase. Ceftazidime structure is not exposed into a conformation that is liable for hydrolysis due to steric factors [38]. Extensive structure-activity studies suggest a role for many of the binding sites present on surface and a detailed explanation was reported [42-44]. A similar phenomena and explanation was outlined for imipenem, which acts as an inhibitor of AmpC β-lactamase and at the same time it is resistant to hydrolysis by this enzyme [45].

The potent binding affinity of the resistant cephalosporins on various  $\beta$ -lactamases indicated, through their low docking scores (Table 3), the strong

binding to these enzymes on certain binding sites located on their surfaces with very low level of binding energy. This is supported by the observation that many




Fig. 8 Docking pose of cephalexin on 1ome.




Fig. 9 Docking pose of ceftazidime on 1ome.





Fig. 10 Docking pose of ceftobiprole on 1ome.

binding sites were identified on  $\beta$ -lactamases, particularly AmpC  $\beta$ -lactamase and several water sites [44, 46]. There are well-defined positions in the binding sites that may accommodate ligand functional groups. The binding affinity of a cephalosporin with a  $\beta$ -lactamase may be a distinguishing factor in the evaluation of  $\beta$ -lactamase-resistance, and have an important role in the susceptibility to highly β-lactamase-resistant cephalosporins [47]. A similar phenomenon was also observed in this study, when ceftazidime and ceftobiprole were docked on  $\beta$ -lactamases, which showed that their  $\beta$ -lactam rings were not accommodated in the active site of  $\beta$ -lactamases to be hydrolyzed (Figs. 9 and 10), but projected away or flipped from the active site. The resistant cephalosporins were bound effectively to the binding sites of the enzyme, as noticed from the docking scores on  $\beta$ -lactamases (Table 3). The relative docking scores of all the investigated cephalosporins were illustrated on a histogram (Fig. 11) showing the main differences in activity and binding affinity to β-lactamases.

# 3.6 Validity of the Docking Study on PBPs and $\beta$ -Lactamases

The application of this molecular docking approach on PBPs and β-lactamases was validated for its reliability as an important source of database screening, prediction and selection of the most potent cephalosporin. Three different methods of information were used for the validation of this approach. The first is based on comparism of the docking scores of the reference cephalosporins selected from different generations of various activities and stabilities. The results have indicated that there was a noticeable decline in the docking scores of the reference cephalosporins as advancing in generations towards the fifth generation. Cephalexin recorded high docking score, while ceftobiprole showed the lowest docking scores. It is well-known that ceftobiprole is the most active with broader spectrum, as indicated from its very low MIC values against various microbes [30]. The second method has included the experimental data of antibacterial activity of the investigated the cephalosporins [24], which have indicated that they





Keynote: Synthesized cephalosporins (1-8), Cephalexin (cn), Cefuroxime (cx), Ceftazidime (cz), Ceftriaxone (cf), Cefozopran (cp) and Ceftobiprole (cb).

comply with the docking scores. The third method is based on the results of the docking study on β-lactamases, which predicted the possible stability of the newer cephalosporins based on docking scores and positioning on surface of  $\beta$ -lactamases. The docking scores of the susceptible cephalosporins, such as cephalexin and cefuroxime were much higher than those of the resistant cephalosporins. The resistant cephalosporins have shown very low docking scores and the lowest was recorded for ceftobiprole. This indicates that these cephalosporins strongly bound to β-lactamases, but are not hydrolyzed. This comparison is a relative study based on docking scores of the resistant and the more potent cephalosporins with the newly synthesized cephalosporins. It is presumed that there is no limitation for such study, as the molecular docking approach can be applied to all types of antibacterial agents that perform their action through affinity binding to PBPs to predict their bioactivity in comparison with the most potent cephalosporins.

# 5. Conclusion

222

The application of molinspiration calculations and molecular docking studies of cephalosporins on β-lactamases and PBPs is considered very useful and practical approach to calculate the molecular properties and predict the bioactivity scores against certain microbes. Molecular docking of the proposed cephalosporins on PBPs could be a reliable and rapid approach for determining the bioactivity scores and thereby selecting the most potent cephalosporin. This approach is also very useful to predict the stability and selectivity of the investigational cephalosporins against β-lactamases of various origins against certain pathogenic microbes including P. auroginosa and / or MRSA. The prediction of docking scores and consequently, the degree of stabilities are recorded as relative values in comparison with reference cephalosporins. Therefore, this method is suggested as a very useful new approach that could be used prior the chemical synthesis of newer cephalosporins.

### Acknowledgment

The author acknowledges the great help of Dr. Sabah J. Salih / quality control department of the Iraqi Ministry of Health. The very useful information of Molinspiration.com and mucle.com are greatly acknowledged. The continuous support of the University of Baghdad is acknowledged.

## References

- Levy, S. B., and Marshall, B. 2004. "Antibacterial Resistance Worldwide: Causes, Challenges and Responses." *Nature Medicine* 10 (12): S122-S129.
- [2] Furtado, G. H. C., Perdiz, L. B., and Medeiros, E. A. S. 2008. "The Effect of a 4th Generation- Cephalosporin Introduction upon the Incidence of Multidrug-Resistant Gram-Negative Bacteria in a Non-Teaching Hospital." *Am. J. Inf. Dis.* 4 (4): 267-71.
- [3] Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheldt, M., Spielberg, B., Bartlett, J., 2009, Bad Bugs, no Drugs: no ESKAPE, *Am. Clin. Inf. Dis.*, 48, 1-12.
- [4] Beale, J. M. Jr. 2011. In: Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 12th eds., Antibacterial Antibiotics, Lippincott Williams and Wilkins, 258-326.
- [5] Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S., Gershman, K., Ray, S., Harrison, L. H., Lynnfield, R., Dumyati, G., Townes, J. M., Craig, A. S., Zell, E. R., Fosheim, G. E., McDougal, L. K., Carey, R. B., and Fridkin, S. K., 2007. "Invasive Methicillin-Resistant *Staphylococcus aureus* Infections in the United States." *J. Am. Med. Assoc.* 298: 1763-71.
- [6] Howden, B. P., Johnson, P. D., Charlesan, P. G., and Grayson, M. L. 2004. "Failure of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Infections." *Clin. Inf. Dis.* 39: 1544-5.
- [7] Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R.C., and Ferraro, M. J. 2001. "Linezolid Resistance in a Clinical Isolate of *Staphylococcus aureus*." *Lancet* 358: 207-8.
- [8] Mangili, A., Bica, I., Snydman, D. R.,and Hamer, D. H. 2005. "Daptomycin-Resistant, Methicillin-Resistant *Staphylococcus aureus* Bacteremia." *Clin. Inf. Dis.* 40: 1058-60.
- [9] Alcaide, B., Aragoncillo, C., and Almendros, P. 2008. "Cephlaosporins" In *Comprehensive Heterocyclic Chemistry III*, edited by Katritzky, A. R. Ed. Elsevier Ltd, Oxford, Chapter 2, 111-72.

- Bassetti, M., Merelli, M., Temperoni, C., and Astilean, A.
   2013. "New Antibiotics for Bad Bugs: Where Are We?" Annals Clinic. Microbiol. Antimicrobial 12: 22.
- [11] Beckwith, C. M. 2011. "Ceftaroline Fosamil." New Drug Bulletin 1-2.
- [12] Henry, X., Amoroso, A., Coyette, J., and Joris, B., 2010.
   "Interaction of Ceftobiprole with the Low-Affinity PBP 5 of Enterococcus Faecium." *Antimicrob. Agents Chemother.* 54 (2): 953-5.
- [13] Cohen, N. C., Blaney, J. M., Humblet, C., Gund, P., and Barry, D. C. 1990. "Molecular Modeling Software and Methods for Medicinal Chemistry." *J. Med. Chem.* 33 (3): 883-94.
- [14] Carlton, A. T., Vinicius, B. da S., Carlos, H., and Tomich, da S. 2008. "Current Topics in Computer-Aided Drug Design." J. Pharm. Sci. 97 (3): 1089-98.
- [15] Girgis, A. S., Tala, S. R., Oliferenko, P. V., Oliferenko, A. A., and Katritzky, A. R., 2012. "Computer-Assisted Rational Design, Synthesis and Bioassay of Non-Steroidal Anti- Inflammatory Agents." *Eur. J. Med. Chem.* 50: 1-8.
- [16] Ambesi-Impiombato, A., and Bernardo, di D., 2006.
   "Computational Biology and Drug Discovery: From Single-Network Drugs." *Current Bioinformatics* 1: 3-13.
- [17] Himaja, M., Ranjitha, A., and Mali, S. V. 2012. "Synthesis, Docking and Anticancer Activity Studies of D-Proline-Incorporated Wainunuamide." *J. Chem. Sci.* 124 (5): 1049-55.
- [18] Garg, V., Kumar, A., Chaudhary, A., Agrawal, S., Tomar P, and Sreenivasan, K. K. 2013. "Synthesis, Biological Evaluation and Molecular Docking Studies of 1,3-benzoxazine Derivatives as Potential Anticancer Agents." *Med. Chem. Res.* 22 (11): 5256-66.
- [19] Sukhbir, L. K., Monga, J., Asif, M. V., and Reetu, H. S. 2013. "Docking Studies on Butenolide Derivatives as Cox-II inhibitors." *Med. Chem. Res.* 22 (11): 5536-44.
- [20] Lingaiah, B. P. V., Yakaiah, T., Shakhar, A. C., Kumar, A. R., Sathaiah, G. R. K., Rao, S. P., Narsaiah, B., Kumar, K. P., Murthy, U. S. N., Purushotham, U., and Sastry, G. N. 2012. "Synthesis of Novel α-Amino Acid Functionalized 6-Fluoroquinolones, Their Antibacterial Activity and Molecular Docking Studies." *Indian J. Chem.* 51B: 969-80.
- [21] Ahmed, A., and Daneshtalab, M. M. 2012. "Polycyclic Quinolones (Part 1) Thieno [2,3-b] benzo[h] Quinoline Derivatives: Design, Synthesis, Preliminary *in vitro* and in Silico Studies." *Heterocycles* 85 (1): 107-22.
- [22] Sinha, R., Vidyarthi, A., and Shankaracharya, A. 2011. "A Molecular Docking Study of Anticancer Paclitaxel and its Analogues." *Ind. J. Biochem. Biophy.* 248 (2): 101-5.
- [23] Alwan, S. M. 2012. "Synthesis and Preliminary Antimicrobial Activities of New Arylideneamino-1,3,4-Thiadiazole-(thio/dithio)

Acetamido Cephalosporanic Acids." *Molecules* 17: 1025-38.

- [24] Lipinski, C. A. 2004. "Lead- and Drug-Like Compounds: The Rule-of-Five Revolution." *Drug Discovery Today Technologie* 1 (4): 337-41.
- [25] Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. 2001. "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Stings." *Adv. Drug Delivery Rev.* 46 (1-3): 3-26.
- [26] Beadle, B. M., and Shoichet, B. K. 2002. "Structural Basis for Imipenem Inhibition of Class C β- Lactamases." *Antimicrob. Agents Chemother* 46 (12): 3978-80.
- [27] Pheleps, D. J., Dennis, D., Carlton, D. D., Farrell, C. A., and Kesslert, R. 1986. "Affinity of Cephalosporins for β-Lactamases as a Factor in Antibacterial Efficacy." *Antimicrob. Agents Chemother*. 29 (5): 845-8.
- [28] Ertl, P., Rohde, B., and Selzer, P. 2000. "Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and its Application to the Prediction of Drug Transport Properties." *J. Med. Chem.* 43 (20): 3714-7.
- [29] Davies, T. A., Page, M. G. P., Shang, W., Andrew, T., Kania, M., and Bush, K. 2007. "Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumonia." *Antimicrob. Agents Chemother.* 51 (7): 2621-4.
- [30] Chang, L.C.W., Spanjersberg, R.F., Frijtag, J.K., Künzel, D., Mulder-Krieger, T., Hout, G.V. Den Beukers, M.W., Brussee, J., Adrian, P., IJzerman, A., 2004, 2,4,6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine A1 Receptor Antagonists. *J. Med. Chem.*, 47 (26), 6529-6540.
- [31] Viswanadhan, V.N., Ghose, A.K.R., Revankar, G.R., Robins, R.K., 1989, Atomic Physicochemical Parameters for Three Dimensional Structure Directed Quantitative Structure-Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occurring Nucleoside Antibiotics. J. Chem. Inf. Comput. Sci., 29 (3), 163-72.
- [32] Clark, D.E., 1999, Rapid Calculation of Polar Molecular Surface Area and its Application to the Prediction of Transport Phenomena. 1. Prediction of Intestinal Absorption. J. Pharm. Sci., 88 (8), 807-14.
- [33] Curtis, N.A., Orr, D., Ross, G.W., Boulton, M.G., 1979, Affinities of Penicillins and Cephalosporins for the Penicillin-Binding Proteins of Escherichia coli K-12 and Their Antibacterial Activity. *Antimicrob. Agents Chemother.* 516 (5), 33-539.
- [34] Tsucfaimori, N., Okonogi, K., 1996, Penicillin-Binding

Protein 5 as an Inhibitory Target of Cefozopran in Enterococcus faecalis, *J. Antimicrob. Chemother.* 37, 605-9.


- [35] Georgopapadakou, N.H., 1993, Penicillin-Binding Proteins and Bacterial Resistance to β-Lactams, *Antimicrob. Agent Chemother*. 37 (10), 2045-53.
- [36] Xavier, H.X., Amoroso, A., Coyette, J., Joris, B., 2010, Interaction of Ceftobiprole with the Low-Affinity PBP 5 of Enterococcus faecium. *Antimicrob. Agents Chemother.* 54 (2), 953-5.
- [37] Parvez, M.A., Shibata, H., Nakano, T., Niimi, S., Fujii, N., Arakaki, N., Higuti, T., 2008, No Relationship Exists between PBP 2a amounts Expressed in Different MRSA Strains obtained Clinically and Their β-Lactam MIC values, *J. Med. Invest.* 55, 246-53.
- [38] Kosowska-Shick, K., McGhee, P.L., Appelbaum, P.C., 2010, Affinity of Ceftaroline and other β-Lactams for PBPs from Staphylococcus aureus and Streptococcus pneumonia. *Antimicrob. Agents Chemother*. 54 (5), 1670-7.
- [39] Roychoudhury, S., Dotzlaf, J.E., Ghag, S., Yeh, W.K., 1994, Purification, Properties, and Kinetics of Enzymatic Acylation with β-Lactams of Soluble Penicillin-binding Protein 2a. J. Biol. Chem. 269, 37, 12067-73.
- [40] Wu, C.Y.E., Hoskins, J., Blaszczak, L.C., Preston, D.A., Skatrud, P.L., 1992, Construction of a Water-Soluble form of Penicillin-Binding Protein 2a from a

Methicillin-Resistant Staphylococcus aureus Isolate. Antimicrob. Agents Chemother. 36 (3), 533-9.


- [41] Chambers, H.F., 1999, Penicillin-Binding Protein–Mediated Resistance in Pneumococci and Staphylococci, J. Infect. Dis., 179 (Suppl. 2) S353-9.
- [42] Williamson, R., Hakenbeck, R., Tomasz, A., 1980, In vivo Interaction of β-Lactam Antibiotics with the PBPs of S. pneumonia. *Antimicrob. Agents Chemother*. 18 (4), 629-37.
- [43] Pucci, M.J., Boice, S., Roberte, J., Kessler, R., Dougharty, T.J., 1991, Comparison of Cefepime, Cefpirome, and Cefaclidine Binding Affinities for Penicillin-Binding Proteins in Escherichia coli K-12 and P. aeruginosa SC8329, *Antimicrob. Agents Chemother.* 35 (11), 2312-7.
- [44] Powers, R.A., Caselli, E., Focia, P.J., Prati, F., Shoichet, B.K., 2001, Structures of Ceftazidime and its Transition-State Analogue in Complex with AmpC β-Lactamase: Implications for Resistance Mutations and Inhibitor Design. *Biochemistry*, 40, 9207-14.
- [45] Powers, R.A., Shoichet, B.K., 2002, Structure-based approach for binding site identification on AmpC β-lactamase. J. Med. Chem., 45, 3222-34.
- [46] Tsukamoto, K., Tachibana, K., Yamazaki, N., Ishii, Y., Ujii, K., 1990, Role of Lysine-67 in the Active Site of Class C β-lactamase from Citrobacter freundii GN346. *Eur. J. Biochem.*, 188, 15-22.

# **Graphical Abstract**

A new approach of using molinspiration calculations and molecular docking on PBPs (penicillin-binding proteins) and certain  $\beta$ -lactamases is employed to predict the activity and resistance of cephalosporins. Cephalosporins are subjected to extensive evaluations on the bases of Lipinski's rule, bioactivity prediction by molinspiration and docking study on PBPs. Docking study on  $\beta$ -lactamases of *E. coli, K. pneumonia, S. aureus* and *P. auroginosa* is also conducted. Docking studies on PBPs and  $\beta$ -lactamases are considered as very useful, reliable and practical for calculating molecular properties, bioactivity scores against certain pathogens, such as *P. auroginosa* and MRSA and to determine the stability of the newer cephalosporins against  $\beta$ -lactamases.



Docking pose of cephalexin on β-lactamase 1ome



Docking pose of ceftobiprole on β-lactamase 1ome